Esophageal cancer remains one of the most prevalent malignancies worldwide. About 85% of esophageal cancers are esophageal squamous cell carcinomas （ESCC）， the incidence of which shows significant geographical correlation and exhibits particularly high prevalence in East Asian countries and regions such as China. With the advent of precision medicine， therapeutic strategies for ESCC have evolved from single-modality approaches to a multidisciplinary comprehensive treatment paradigm encompassing surgical resection， systemic chemotherapy， radiotherapy， and immunotherapy. As one of the core treatment methods for ESCC， radiotherapy has made remarkable progress in recent years， driven by technological innovation and the coordinated development of multiple disciplines.